Biora Therapeutics, Inc. (BIOR) Monday announced positive data from its clinical trial of BT-600 for the potential treatment of patients with ulcerative colitis. BT-600 leverages Biora's ingestible NaviCap device to deliver a proprietary liquid formulation of tofacitinib directly to the colon.
The company said the Phase 1 trial involving 48 healthy volunteers met all trial objectives, suggesting pan-colonic delivery, specifically to the location of the disease. Further, the daily dose was well tolerated.
Adi Mohanty, Chief Executive Officer of Biora Therapeutics said, "Our anatomically targeted approach has the potential to improve the efficacy of JAK inhibitors and other drug classes. We envision a portfolio of NaviCap-delivered therapeutics unlocking new treatment potential for patients with GI diseases."
Biora said, the first evidence of systemic absorption of tofacitinib was at six hours, consistent with colonic delivery. Maximal levels in the trial occurred at eight to ten hours vs. 30 minutes for conventional oral tofacitinib in other trials.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.